Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination ...

Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.

For me, there is something about the Olympic flame that bridges the gap between the ancient dust of Olympia and the high-tech arenas of today.

Introduction** Relay Therapeutics, Inc. (NASDAQ: RLAY) has recently caught the attention of investors following an upgrade from Oppenheimer. Analyst Matthew Biegler awarded the stock an “Outperform” ...

A recent upgrade for Relay Therapeutics, Inc. (NASDAQ: RLAY) to an Overweight rating by Eva Fortea Verdejo of Wells Fargo highlights the growing confidence in the company’s prospects. With a current ...

Littelfuse, Inc. has introduced the CPC1056N, a compact, high-performance 60 V, 75 mA 1-Form-A solid-state relay (SSR) designed to meet the growing demand for fast, efficient and space-saving ...

Iceland declares threat to Atlantic Ocean current a national security risk Scientists warn current collapse could trigger modern-day ice age for Northern Europe Researchers working to understand how, ...

Littelfuse, Inc. introduced the CPC1056N, a compact, high-performance 60 V, 75 mA 1-Form-A solid-state relay (SSR) designed to meet the growing demand for fast, ... Littelfuse, Inc. announced the ...

The current collective bargaining agreement between the WNBA and Women's National Basketball Players Association (WNBPA) was set to expire Friday, but the two sides have agreed to a 30-day extension, ...